In another context of disease, therapeutic inhibition of MSR1, via monoclonal antibody treatment, decreased the release of TNF-α both in an NAFLD mouse model and in ex vivo human liver (76). Here, MSR1 is linked to metabolic dysfunction-associated steatotic liver disease.